


On-line Table. Baseline demographics, angiographic, and clinical characteristics of patients who experienced coil prolapse associated with embolization with follow-up data

Patient No.	Age (yr)/Sex	Aneurysm Location	Initial Protrusion Grade	Last Follow-Up Protrusion Grade	SAH Grade	Size of Aneurysm	Medical Treatment	Endovascular Treatment	Coils Used ^a	Discharge mRS	Events at 1 mo	Follow-Up Angiogram (mo)	mRS at 6 mo	Length of Follow-Up (mo)	Events during Follow-Up	mRS at Last Contact
1	40/F	L ICA paraophthalmic	II	II	HH 4	13 × 11 mm	Aspirin, 325 mg × 1 mo, Aspirin 81 mg indefinitely, enoxaparin × 6 mo	Rescue balloon, HyperGlide 4 × 10 mm	13 (3 GDC, 6 Matrix, 4 HydroCoil)	4	ICH due to therapeutic heparin (day 20)	18	2	18	None	1
2	33/M	AcomA	II	II	HH 1	4.5 × 4.5 mm	Aspirin 325 mg indefinitely	None	3 (GDC)	3	None	12	2	12	None	1
3	48/M	L ICA	I	0	HH 1	12 × 9 mm	Aspirin 325 mg × 1 mo, clopidogrel 75 mg × 5 days	None	6 (3 Cashmere, 2 Ultipa, 1 Presidio)	1	None	6	0	6	None	0
4	39/M	AcomA	I	I	HH 1	8.5 × 10.5 mm	Aspirin 325 mg × 1 mo	None	19 (4 Cashmere, 4 Micrusphere, 8 Ultipa, 1 Presidio, 1 HydroCoil, 1 Hydrosort)	1	None	Unknown	1	18	None	0
5	52/F	Basilar	I	I	HH 3	2.5 × 3.5 mm	Aspirin 325 mg × 21 days	None	4 (2 MicroPlex, 1 Hypersoft, 1 helical HydroCoil)	6	Ischemic stroke on day 8, died on day 21	N/A	N/A	N/A	N/A	6
6	48/M	AcomA	I	I	HH 5	12 × 8 mm	Abciximab IA, aspirin 325 mg × 5 days, clopidogrel 300 mg × 1	None	14 (6 Cashmere, 8 Ultipa)	6	Ischemic stroke on day 2, died on day 5	N/A	N/A	N/A	N/A	6
7	51/F	AcomA	III	III	HH 5	13.5 × 10 mm	Eptifibatid IA, aspirin 325 mg × 4 days, clopidogrel 75 mg × 4 days	None	6 (3 Cashmere, 2 Deltapaq, 1 Ultipa)	6	Ischemic stroke on day 3, died on day 4	N/A	N/A	N/A	N/A	6
8	46/F	R ACA	I	I	HH 3	3.5 × 3.5 mm	Aspirin 325 mg indefinitely	None	2 (1 MicroPlex, 1 Hypersoft)	2	None	18	1	18	None	0
9	55/M	AcomA	III	III	HH 1	6 × 3 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 1 mo	Enterprise stent, 4.5 × 22 mm	3 Orbit Mini Complex	2	None	6	1	6	None	1
10	42/F	L ICA paraophthalmic	II	II	HH 3	8 × 6 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 3 months	Neuroform stent 4.5 × 20 mm	5 (3 Cashmere, 2 Ultipa)	3	None	N/A	6	5	Died on day 150	6
11	55/F	AcomA	I	I	HH 3	9 × 4 mm	Eptifibatid IV, aspirin 325 mg × 1 mo, aspirin 81 mg indefinitely	Rescue balloon, Hyperform, 4 × 7 mm	4 (Micrus, Cerecye, Ultipa, Cashmere)	1	None	3	0	15	None	0
12	72/F	L pericallosal	III	III	HH 3	2 × 3 mm	Aspirin 325 mg × 7 days	None	4 (3 Hypersoft, 1 Ultipa)	6	Ischemic stroke on day 4, died on day 7	None	N/A	N/A	N/A	6
13	42/F	L ICA	I	I	HH 1	4.5 × 6 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 3 mos	None	4 (2 GDC, 1 Ultipa, 1 MicroCoil)	3	None	6	1	12	None	1
14	43/F	L ACA	III	0	HH 3	8 × 6 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 3 months	Neuroform stent, 4.5 × 20 mm	6 (MicroPlex, 4 HydroCoil)	3	None	4	N/A	4	None	1
15	49/F	R ICA supraclinoid	I	I	HH 2	5 × 4 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 3 mo	Neuroform stent, 4.5 × 15 mm	4 Matrix	1	None	12	1	12	None	0
16	34/F	AcomA	II	II	HH 1	7 × 4 mm	Aspirin 325 mg indefinitely	None	6 Matrix	1	None	3	N/A	3	None	0
17	48/F	R ICA supraclinoid	III	III	HH 3	3 × 4 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 12 mo	Neuroform stent, 4 × 20 mm	2 Matrix	2	None	48	1	48	None	0
18	60/F	L paraophthalmic	III	III	HH 3	6 × 5 mm	Aspirin 325 mg indefinitely, clopidogrel 75 mg × 6 mo	Neuroform stent, 4.5 × 20 mm	2 Micrus	1	None	6	0	6	None	0
19	41/F	L PcomA	I	I	HH 4	3 × 2 mm	None	None	1 Matrix	2	None	24	0	24	None	0
19	41/F		I	I												

Note:—The grading scheme was used as illustrated in Fig 1.
^a Cashmere (Micrus), Ultipa (Micrus), Deltapaq (Micrus), Presidio (Micrus), MicroPlex (MicroVention), Hydrosort (MicroVention), and Hypersoft (MicroVention), Cerecye (Micrus), HyperGlide (ev3), HyperForm (ev3).



On-line Figure. Flow chart. EVD indicates external ventricular drainage.